■这项回顾性研究旨在评估机械旋转椅辅助的多个耳石重新定位程序(CRP)治疗良性阵发性位置性眩晕(BPPV)的有效性和不良反应。
■对1,273例BPPV患者进行了回顾性分析,241名患者纳入最终研究。参与者诊断为BPPV,以前的CRP无法解决,分为单个或多个CRP组。在这两组中,在初始治疗后的第1、4和7天,参与者在单一CRP后重新评估;如果位置性眩晕得到解决,治疗被认为是成功的。缓解率,不利影响(如运河开关(CS),falls,和呕吐),残余头晕(RD)率,比较两组的RD持续时间。
■在第1天和第4天,单个和多个CRP组的分辨率显着不同(55.7%vs.85.1%,75.5%vs.91.9%;P<0.05),但在第7天没有(93.3%vs.94.8%;P>0.05)。在CS和跌倒方面,单个和多个CRP组之间没有显着差异(3.8%vs.5.2%,10.3%vs.8.9%;P>0.05)。然而,呕吐的发生率有显著差异(6.6%vs.14.8%;P<0.05)。RD如头部沉重,不平衡,非特异性头晕在单CRP组中比在多CRP组中更常见(34.9%vs.20.7%,42.5%vs.26.7%,47.2%vs.32.6%;P<0.05)。与单一CRP组相比,多次CRP组的RD发生率和持续时间明显减少,发病率分别为41.5%和57.5%,分别为(P<0.05)。
■对于BPPV患者,多个CRP比单个CRP提供更大的益处.
UNASSIGNED: This retrospective study aimed to assess the effectiveness and adverse effects of mechanical rotational chair-assisted multiple canalith repositioning procedures (CRPs) to treat benign paroxysmal positional vertigo (BPPV).
UNASSIGNED: A retrospective analysis of 1,273 BPPV patients was conducted, with 241 patients included in the final study. The participants diagnosed with BPPV, unresolved by a single previous CRP, were categorized into either the single or multiple CRP groups. In both groups, on days 1, 4, and 7 after the initial treatment, the participants were re-evaluated after a single CRP; if positional vertigo was resolved, the treatment was regarded as successful. The remission rate, adverse effects (such as canal switch (CS), falls, and vomiting), residual dizziness (RD) rate, and RD duration were compared between the two groups.
UNASSIGNED: The resolution rates for the single and multiple CRP groups were significantly different on days 1 and 4 (55.7% vs. 85.1%, 75.5% vs. 91.9%; P < 0.05) but not on day 7 (93.3% vs. 94.8%; P > 0.05). There were no significant differences between the single and multiple CRP groups in terms of CS and falls (3.8% vs. 5.2%, 10.3% vs. 8.9%; P > 0.05). However, there was a significant difference in the incidence of vomiting (6.6% vs. 14.8%; P < 0.05). RD such as head heaviness, imbalance, and non-specific dizziness is more common in the single CRP group than in the multiple CRP group (34.9% vs. 20.7%, 42.5% vs. 26.7%, 47.2% vs. 32.6%; P < 0.05). The incidence and duration of RD were notably diminished in the group undergoing multiple CRPs compared to the single CRP group, with incidence rates of 41.5% and 57.5%, respectively (P < 0.05).
UNASSIGNED: For patients with BPPV, multiple CRPs offer greater benefits than a single CRP.